DLH bottoms out of the bathtub: CMOP ends, a two-year NIH bridge lands, health-budget cuts loom
The small federal-services contractor walks away from its VA pharmacy staffing work, right-sizes costs, and bets a revived defense-led pipeline will lift it out of a four-year drawdown.
DLHC · Earnings Call · 2026-05-07
DLH Holdings Corp. came to its fiscal second-quarter call a smaller, leaner company — and, management hopes, one finally on the other side of a long slide. Revenue fell 34% year over year to $59 million, the third straight quarter of contraction as the prior administration's small-business set-aside mandate finished dismantling the portfolio's two biggest anchors — the VA's mail-order pharmacy (CMOP) operations and the HHS Head Start program. Net income swung to a -$3 million loss, and operating margin printed at -5.4%, the first negative quarter in a decade.
But the message from management was pointedly forward-looking: the supply-side losses are done, the procurement drought is breaking, and a rebalanced federal budget finally favors the defense and intelligence work where DLH has invested its data science and digital-modernization capabilities. The keyword record shows the narrative arc plainly — "VA CMOP" and "Head start" dominated the past year of vocabulary; this quarter, "budget cycle," "cost scaling," and procurement timing take over.
The wrap-up that matters
The single most important change is that the CMOP story now has a firm end date. CFO Kathryn Johnbull told the analyst the final locations wind down “just before Memorial Day,” — Kathryn M. Johnbull, Chief Financial Officer · 2026-05-07 and CEO Zachary Parker explained why the company is walking away rather than fighting it:
once the VA changed that acquisition process, not only to small business set-aside, but changed it from being a solutions- and tech-derived execution to just butts-in-seats, we withdrew all of our joint venture bids and approached it accordingly. So it is bittersweet.
That "butts-in-seats" framing matters — DLH isn't losing a solutions contract, it's choosing not to bid on a staffing one. The VA CMOP wind-down removes roughly a $24-million-per-quarter revenue drag that had been the dominant headwind for two years — the same run-rate Johnbull once guided as continuing revenue “approximately 23 million to 25 million for the remaining locations that we expect to extend.” — Kathryn JohnBull, Chief Financial Officer · 2025-05-10 That revenue is now exiting, and the cost base is sized accordingly.
Where the February call framed cost scaling as an ongoing program, Johnbull now says the material work is finished — "we have accomplished the material reductions that are necessary to right-size the business" — with only routine lease and footprint reviews continuing. The balance sheet is cooperating: total debt fell to $132.7 million, resuming the deleveraging trend after a seasonal Q1 uptick, with a target to convert 50–55% of fiscal 2026 EBITDA into debt reduction.
A bridge across a new budget risk
The late-breaking news was a two-year sole-source extension of a clinical research support contract with the National Institutes of Health — a genuine positive in a four-quarter streak of losses. Johnbull put its value plainly: “anytime an important part of your portfolio gets an extension and gives you additional revenue visibility, that is always very welcomed.” — Kathryn M. Johnbull, Chief Financial Officer · 2026-05-07 For a company whose Public Health pillar has been its identity for decades, the bridge buys two years of certainty on exactly the segment now facing the sharpest budget scrutiny.
That scrutiny is the newest — and sharpest — strategic overhang. The FY2027 President's budget request calls for historic spending increases in the defense and intelligence sector, partially offset by unspecified reductions in federal health spending. DLH sits precisely at that seam: defense/intel up, health down. The NIH extension is a partial hedge, but the exposure is real.
The bathtub versus the V-curve
The deeper architecture of the story is timing. DLH built its organic-growth engine for a 2024–2025 bid cycle that never materialized — the stalled economy, acquisition-officer cuts, and the budget shutdown froze procurement. The contrast with the prior quarter is stark. In February, Parker described a near-total drought: “We had 1 bid opportunity for the entire month of January. And that's just really, really trickling.” — Zachary C. Parker, President and Chief Executive Officer · 2026-02-10 Now he reports several material RFPs have already come through, bids have been submitted, and he expects decisions by this fiscal year.
“What we thought was going to be a pretty quick V-curve turned out to become a little more of a bathtub, but we are starting to see the opportunities hit now and certainly feel that we will be able to compete favorably for our share.” — Zachary C. Parker, President and Chief Executive Officer · 2026-05-07
That's the investment case in one line: DLH has absorbed the program losses, resized the cost base, and now finally faces a live pipeline — with the caveat that each large award carries protest risk and the health-budget blade hangs over its public-health pillar.
The numbers support a "bottoming" read. Operating margin at -5.4% and -$3M of operating income mark the trough quarter of a reset, not an operational unraveling. Revenue ($59M) has retraced to pre-acquisition scale. The balance sheet is the real tell — net leverage is deleveraging after peaking through the transition, comfortably ahead of mandatory repayments.
For an ~$80M-market-cap services name that has shed nearly 79% from its 2021 peak and another 26% over the past 90 days, the thesis has never been cleaner — or more binary. The bathtub is real, the defense-intel tailwind is real, and the NIH bridge is real. But the federal health cut is coming, and DLH is still early in proving it can convert a revived pipeline into revenue. The market will grade each summer award decision.